SHOULDER & ELBOW
COA/ICORS2019: No effect on fracture healing, improved ROM with ketotifen fumarate for reducing PTJC
91 patients with elbow fractures included in the PERK clinical trial study were included in this sub-group analysis comparing fracture healing, functional outcomes and adverse events between oral ketotifen fumarate treatment and placebo. Follow up was performed at 12 and 52 weeks. Results revealed no significant differences between the ketotifen fumarate and placebo groups in fracture healing, incidence of heterotopic ossification, DASH scores, and incidence of serious adverse events. Range of motion in the flexion-extension arc of the elbow was significantly favourable in the ketotifen fumarate group at 12 weeks.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
